Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Post by Ingiboyon Jan 16, 2025 11:39am
68 Views
Post# 36407236

What if the Purchase Agreement is not approved ?

What if the Purchase Agreement is not approved ?Not sure if all the shareholders received the information circular for the AGM to be held today.  There is some very interesting reading related to the Purchase Agreement not being approved by the eligible shareholders:

"Registered  shareholders have the right to exercise Dissent Rights and to demand payment equal to the fair value of the common shares ...."

"Certain costs related to the Transaction such as legal, accounting and other fees, must be paid by the company (Replicel) even if the Transaction is not completed.  The Company is liable for all of its costs incured to date in connection with the Transaction".

According to the information circular there are 73,577,807 common shares outstanding.  There are 
20,699,472  (28%) common share ineligible to vote.  The Purchase Agreement must receive a
66 2/3% approval. Do the math. 
<< Previous
Bullboard Posts
Next >>